Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Stock Information for Avalo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalo Therapeutics Inc.

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Reports 2023 Financial Results and Provides Business Updates
Avalo Acquires Anti-IL-1? mAb and Announces Private Placement Financing of up to $185 Million
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
Avalo Completes Divestiture of AVTX-800 Series
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.